Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PTPRB | P23467 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 3/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12207085 | 0.82 | MCL1 (0.62) | MCL1L3MBTL1HPGDTHRBTHRA | |
| SCHEMBL18480013 | 0.81 | RAB9A (0.53) | MCL1L3MBTL1THRBLMNA | |
| SCHEMBL2381680 | 0.81 | MCL1 (0.44) | MCL1L3MBTL1HPGDPTPRBHSD17B10 | |
| SCHEMBL15464819 | 0.81 | MCL1 (0.70) | MCL1L3MBTL1HPGDPTPRBHSD17B10 | |
| SCHEMBL2380557 | 0.79 | THRB (0.43) | MCL1L3MBTL1HPGDPTPRBHSD17B10 | |
| SCHEMBL2380761 | 0.78 | ALDH1A1 (0.51) | HPGDPTPRBHSD17B10THRBTHRA | |
| SCHEMBL3731595 | 0.78 | L3MBTL1 (0.67) | MCL1L3MBTL1HPGDTSHRMMP2 | |
| SCHEMBL3723832 | 0.77 | L3MBTL1 (0.66) | MCL1L3MBTL1HPGDTSHRMMP2 | |
| SCHEMBL4072199 | 0.76 | MCL1 (0.62) | MCL1L3MBTL1HPGDPTPRBHSD17B10 | |
| SCHEMBL16480582 | 0.74 | MCL1 (0.69) | MCL1L3MBTL1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110313144-A1 | iRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | ALNYLAM PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313144-A1 | iRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | CCR5, CXCR3, CCR2 | MCL1 653/4885L3MBTL1 1967/4885HPGD 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.